Pharma BD Deal Intelligence

bioMerieux SA / BioFire Diagnostics Inc.

2013 · Acquisition/Merger · $485M · Complete

Strongly positive — critic reaction at announcement

Worked — the deal delivered on its rationale

CALLED IT — OFF BY 0

bioMerieux acquired BioFire Diagnostics (formerly Idaho Technology) for $450 million plus approximately $35 million in net debt (EUR 355 million total). BioFire's FilmArray multiplex PCR system, which integrates sample preparation, amplification, detection and analysis into one device, became a cornerstone of bioMerieux's syndromic diagnostics strategy.

Key facts

Announced Sep 04, 2013
Closed Jan 16, 2014
Deal value $485M
Deal type Acquisition/Merger
Therapeutic area Infectious Disease, Respiratory
Indications Respiratory Infections, Blood Stream Infections, Gastrointestinal Infections, Meningitis/Encephalitis
Key assets FilmArray multiplex PCR system, FilmArray Respiratory Panel, FilmArray Blood Culture Identification Panel, BioFire R&D pipeline
Mechanism Multiplex PCR, Syndromic molecular diagnostics

Related deals — scored

Deal	Year	Value	Outcome
bioMerieux SA / BioFire Diagnostics Inc. (this deal)	2013	$485M	88
Pfizer Inc. / BioNTech SE	2020	$748M	100
Gilead Sciences Inc. / Pharmasset Inc.	2011	$11.2B	98
Abbott Laboratories / Alere Inc.	2016	$5.8B	95
Roche Holding AG / Ventana Medical Systems Inc.	2008	$3.4B	88
AstraZeneca PLC / MedImmune Inc.	2007	$15.6B	82
GSK plc / SmithKline Beecham	2000	$12.0B	79

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals

More: 2013 deals · Infectious Disease deals